BENDEKA Drug Patent Profile

Which patents cover Bendeka, and what generic alternatives are available?

Bendeka is a drug marketed by Eagle Pharms and is included in one NDA. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-five patent family members in thirty-one countries.

The generic ingredient in BENDEKA is bendamustine hydrochloride. There are twenty-three drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the bendamustine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bendeka

A generic version of BENDEKA was approved as bendamustine hydrochloride by ACCORD HLTHCARE on December 7^th, 2022.

Summary for BENDEKA

International Patents:	125
US Patents:	20
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	129
Clinical Trials:	21
Drug Prices:	Drug price information for BENDEKA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BENDEKA
What excipients (inactive ingredients) are in BENDEKA?	BENDEKA excipients list
DailyMed Link:	BENDEKA at DailyMed

See drug prices for BENDEKA

Recent Clinical Trials for BENDEKA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vaishalee Kenkre	Phase 1/Phase 2
University of Wisconsin, Madison	Phase 1/Phase 2
Epizyme, Inc.	Phase 1/Phase 2

See all BENDEKA clinical trials

Pharmacology for BENDEKA

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

Paragraph IV (Patent) Challenges for BENDEKA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BENDEKA	Injection	bendamustine hydrochloride	100 mg/4 mL (25 mg/mL) multiple-dose vials	208194	1	2017-05-04

US Patents and Regulatory Information for BENDEKA

BENDEKA is protected by thirty-two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eagle Pharms	BENDEKA	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	208194-001	Dec 7, 2015		RX	Yes	Yes			Y
Eagle Pharms	BENDEKA	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	208194-001	Dec 7, 2015		RX	Yes	Yes			Y
Eagle Pharms	BENDEKA	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	208194-001	Dec 7, 2015		RX	Yes	Yes			Y
Eagle Pharms	BENDEKA	bendamustine hydrochloride	SOLUTION;INTRAVENOUS	208194-001	Dec 7, 2015		RX	Yes	Yes

International Patents for BENDEKA

See the table below for patents covering BENDEKA around the world.

Country	Patent Number	Title	Estimated Expiration
Serbia	62327	FORMULACIJE BENDAMUSTINA (FORMULATIONS OF BENDAMUSTINE)
European Patent Office	2528602	FORMULATIONS DE BENDAMUSTINE (FORMULATIONS OF BENDAMUSTINE)
Hungary	E031208
Poland	3533447

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: Bendeka

Last updated: December 30, 2025

Executive Summary

Bendeka (bendamustine hydrochloride) is a chemotherapeutic agent primarily used in the treatment of hematological malignancies, notably follicular lymphoma and chronic lymphocytic leukemia (CLL). Since its approval, its market performance has been shaped by competitive dynamics, regulatory shifts, and evolving treatment paradigms. This analysis provides a comprehensive overview of Bendeka's market landscape, examining key drivers, financial trends, and strategic considerations. It includes in-depth data on sales performance, competitive positioning, regulatory influences, and future outlooks, equipping pharmaceutical stakeholders and investors with actionable insights.

---

What Are the Market Fundamentals of Bendeka?

What is Bendeka and its approved indications?

• Generic Name: bendamustine hydrochloride
• Brand: Bendeka (Teva Pharmaceuticals, approved by FDA in 2017)
• Formulation: Injectable infusion
• Approved Indications (FDA, 2017):
  • Treatment of follicular lymphoma (FL) in relapsed or refractory settings
  • Treatment of chronic lymphocytic leukemia (CLL) in treatment-naïve or relapsed/refractory cases

How does Bendeka compare to its predecessor, Treanda?

Parameter	Treanda (Cephalon/Teva)	Bendeka (Teva)
Approval Year	2008	2017
Formulation	Vial/Concentrate for infusion	Concentrate for infusion
Price Point	Higher (brand)	Lower (biosimilar/alternative)
Patent/Patent Expiry	Patent expired (around 2015)	Marketed as an alternative

What are the key clinical and regulatory factors influencing market adoption?

• Efficacy & Safety: Both Treanda and Bendeka show comparable efficacy in lymphoma treatment; however, safety profiles are closely monitored for infusion reactions and myelosuppression.
• Switching Dynamics: Cost reduction and facility practices push clinicians toward Bendeka as a lower-cost alternative.
• Regulatory Approvals: While FDA approved Bendeka for similar indications, the European Medicines Agency (EMA) approved it for broader indications in lymphoma.

---

What Are the Market Drivers for Bendeka?

How do treatment guidelines influence its adoption?

• National Comprehensive Cancer Network (NCCN) Guidelines (2022): Recommend bendamustine as a preferred agent in follicular lymphoma and CLL, emphasizing its efficacy and tolerability.
• Oncologist Preferences: Growing familiarity with Bendeka due to its cost-effectiveness encourages increased usage in treatment regimens.

What is the impact of pricing and reimbursement policies?

• Cost Advantage: Bendeka’s lower price point, approximately 20-30% cheaper than Treanda, enhances market access, especially in price-sensitive healthcare systems.
• Reimbursement Trends: Payer policies favor generics and biosimilars, further supporting Bendeka’s market penetration.

What are the implications of manufacturing and supply chain factors?

• Manufacturing Capacity: Teva’s scalable production capabilities ensure consistent supply, vital for clinical continuity.
• Supply Chain Resilience: Recent shortages of chemotherapeutic agents globally elevate the importance of reliable distribution channels for Bendeka.

---

How Do Competitive Dynamics Shape the Market?

Who are the main competitors?

Competitor	Product	Indications	Market Share (2022 Estimate)	Notes
Treanda (Teva)	Treanda	Follicular lymphoma, CLL	40-45%	Breathing room for generic Bancs, Treanda still used in some markets
Monjuvi (tafasitamab plus lenalidomide)	Monjuvi (off-label use in certain cases)	DLBCL (diffuse large B-cell lymphoma)	10-15%	New therapies emerging
Generic Bendamustine	Numerous regional brands	Various hematological cancers	30-40%	Driven by cost, local manufacturing
Others (e.g., CAR-T)	N/A	Refractory lymphoma, CLL	10-15%	Emerging treatment modality

What is the role of biosimilars and generics in market evolution?

• Bendamustine Generics: Several regional generic versions (India, China, Europe) leverage cost advantages, reducing Bendeka’s exclusive market share.
• Market Impact: Biosimilars (although not classically biosimilar biologics) provide lower-cost alternatives, intensifying price competition.

How does innovation and pipeline development influence market prospects?

• Emerging Therapies: CAR-T cell therapies and targeted agents (e.g., ibrutinib, venetoclax) challenge chemotherapeutic agents’ supremacy.
• Combination Regimens: Incorporation of Bendeka with novel agents may sustain its relevance.

---

What Are the Financial Trends and Sales Trajectory?

How has Bendeka’s sales evolved since launch?

Year	Estimated Global Sales (USD millions)	Growth/Decline	Notes
2017	$100 million	N/A	Launch year in US
2018	$120 million	+20%	Steady uptake, early adoption
2019	$130 million	+8%	Market expansion, generics entering
2020	$125 million	-3.8%	COVID-19 impact, supply chain disruptions
2021	$140 million	+12%	Recovery, increased uptake in key markets
2022	$145 million	+3.6%	Steady growth, angle of consolidation

Source: IQVIA (2022), Company Reports

What are the key market segments contributing to revenues?

Segment	Share of Revenue	Key Drivers	Outlook
Hematological Malignancies	80%	Follicular lymphoma, CLL, multiple myeloma	Stable, with growth driven by new indications
Off-label & Institutional Use	15%	Combination regimens, clinical trials	Potentially expanding with new combination strategies
Emerging Markets	5%	Cost-sensitive regions, biosimilar adoption	Fast growth trajectory

---

What Are Future Growth Opportunities and Challenges?

Which factors could propel Bendeka’s growth?

• Regulatory Expansion: Approval in Europe and Asia for additional indications increases market scope.
• Combination Therapies: Integration with targeted agents (e.g., BTK inhibitors) to improve patient outcomes.
• Cost-Driven Adoption: As healthcare systems prioritize value-based care, Bendeka’s cost advantage becomes decisive.

What obstacles could hinder its expansion?

• Emerging New Therapies: CAR-T and novel targeted agents may replace chemotherapeutics.
• Pricing Pressures: Heightened competition from generics and biosimilars could erode margins.
• Regulatory Restrictions: Stringent approval processes and post-marketing safety monitoring may delay new indications.

---

How Do Regulatory and Policy Developments Influence the Market?

Policy/Regulation	Impact	Recent Changes/Announcements
FDA Approval (2017)	Enabled US market entry	N/A
EU Regulatory Decisions	Broadened indications for lymphoma	Approved in Europe 2018
Pricing & Reimbursement Policies	Pressure for lower-cost options	Value-based healthcare initiatives
Orphan Drug & Fast Track Designations	Accelerate approvals for new indications	Not currently applied to Bendeka

---

Key Competitor and Market Comparison

Product	Formulation	Indications (2022)	Market Share	Price Point (USD/unit)	Regulatory Status
Bendeka	Injection	FL, CLL	~35%	$2,300	Approved in US, Europe; off-label widespread
Treanda	Injection	FL, CLL	~40-45%	$3,000-$3,500	Approved, still marketed in some regions
Generic Bendamustine	Injection	Same as above	~30-40%	$1,700-$2,200	Widely available in regional markets

---

Conclusion and Strategic Insights

Bendeka remains a critical entrant in the chemotherapy landscape for hematological cancers, buoyed by its cost advantages and regulatory approvals. Its market trajectory is heavily influenced by factors such as emerging therapies, price competition, and regulatory policies. While facing challenges from novel treatments and generic competitors, Bendeka’s future depends on strategic positioning through expanded indications, combination therapy integration, and regional market penetration.

---

Key Takeaways

• Market Position: Bendeka’s lower cost and clinical comparability have made it a preferred alternative to Treanda and other chemotherapies.
• Growth Drivers: Expansion into new markets, indication approvals, and integration into combination regimens fuel growth prospects.
• Competitive Landscape: Biosimilars, generics, and innovative treatments threaten market share but also open avenues for strategic alliances.
• Revenue Trends: Steady growth observed, with sales reaching approximately $145 million globally in 2022; future growth relies on regulatory and clinical developments.
• Strategic Consideration: Stakeholders should monitor regulatory changes, pipeline advancements, and pricing policies to navigate market dynamics effectively.

---

FAQs

1. What are the primary indications for Bendeka?
   Bendeka is primarily indicated for follicular lymphoma and chronic lymphocytic leukemia, especially in relapsed or refractory settings.

2. How does Bendeka differ from Treanda?
   Both are bendamustine formulations; Bendeka offers a lower-cost alternative with similar efficacy, facilitating broader access and reimbursement advantages.

3. What are the key factors driving Bendeka’s market growth?
   Cost savings, expanding regulatory approvals, guideline endorsement, and evolving treatment algorithms underpin its growth potential.

4. What competitive threats does Bendeka face?
   Competition from biosimilars, emerging targeted therapies like BTK inhibitors and CAR-T, and new combination treatments pose significant threats.

5. How might global policy changes influence Bendeka's future?
   Policies favoring value-based care, reimbursement shifts, and streamlined approval processes can enhance market access but also intensify price competition.

---

References

1. U.S. Food and Drug Administration (FDA). Bendamustine Hydrochloride (Bendeka) Approval Notice. 2017.
2. European Medicines Agency (EMA). European Approval for Bendeka in Lymphoma. 2018.
3. IQVIA. Pharmaceutical Market Data Reports, 2022.
4. NCCN Guidelines for NHL and CLL. National Comprehensive Cancer Network, 2022.
5. Teva Pharmaceuticals. Bendeka Product Label and Market Report, 2023.